Search

Your search keyword '"El ‐ Hariry, Iman"' showing total 18 results
Start Over Author "El ‐ Hariry, Iman" Publication Year Range Last 3 years
18 results on '"El ‐ Hariry, Iman"'

1. A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.

Author

Yin, Chao, primary, Marshall, John, additional, Macke, Laura Ann, additional, He, Aiwu Ruth, additional, Bouker, Kerrie, additional, Weinberg, Benjamin Adam, additional, Mukherji, Reetu, additional, Weiner, Louis M., additional, Wang, Hongkun, additional, Geng, Xue, additional, Hoke, Frank, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Noel, Marcus Smith, additional

Published
2023
Full Text
View/download PDF

2. Data from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 2 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 1 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 4 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Methods and Figure Legends from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 3 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Author

Sang, Jim, primary, Acquaviva, Jaime, primary, Friedland, Julie C., primary, Smith, Donald L., primary, Sequeira, Manuel, primary, Zhang, Chaohua, primary, Jiang, Qin, primary, Xue, Liquan, primary, Lovly, Christine M., primary, Jimenez, John-Paul, primary, Shaw, Alice T., primary, Doebele, Robert C., primary, He, Suqin, primary, Bates, Richard C., primary, Camidge, D. Ross, primary, Morris, Stephan W., primary, El-Hariry, Iman, primary, and Proia, David A., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 4 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Methods from A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

Author

Socinski, Mark A., primary, Goldman, Jonathan, primary, El-Hariry, Iman, primary, Koczywas, Marianna, primary, Vukovic, Vojo, primary, Horn, Leora, primary, Paschold, Eugene, primary, Salgia, Ravi, primary, West, Howard, primary, Sequist, Lecia V., primary, Bonomi, Philip, primary, Brahmer, Julie, primary, Chen, Lin-Chi, primary, Sandler, Alan, primary, Belani, Chandra P., primary, Webb, Timothy, primary, Harper, Harry, primary, Huberman, Mark, primary, Ramalingam, Suresh, primary, Wong, Kwok-Kin, primary, Teofilovici, Florentina, primary, Guo, Wei, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Methods, Figure Legend from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 1 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Author

Proia, David A., primary, Zhang, Chaohua, primary, Sequeira, Manuel, primary, Jimenez, John-Paul, primary, He, Suqin, primary, Spector, Neil, primary, Shapiro, Geoffrey I., primary, Tolaney, Sara, primary, Nagai, Masazumi, primary, Acquaviva, Jaime, primary, Smith, Donald L., primary, Sang, Jim, primary, Bates, Richard C., primary, and El-Hariry, Iman, primary

Published
2023
Full Text
View/download PDF

15. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia

Author

Lynggaard, Line Stensig, Vaitkeviciene, Goda, Langenskiöld, Cecilia, Lehmann, Anne Kristine, Lähteenmäki, Päivi M, Lepik, Kristi, El Hariry, Iman, Schmiegelow, Kjeld, Albertsen, Birgitte Klug, Lynggaard, Line Stensig, Vaitkeviciene, Goda, Langenskiöld, Cecilia, Lehmann, Anne Kristine, Lähteenmäki, Päivi M, Lepik, Kristi, El Hariry, Iman, Schmiegelow, Kjeld, and Albertsen, Birgitte Klug

Abstract

Asparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase-related hypersensitivity causes treatment discontinuation, which is associated with decreased event-free survival. To continue asparaginase treatment after hypersensitivity, a formulation of asparaginase encapsulated in erythrocytes (eryaspase) was developed. In NOR-GRASPALL 2016 (NCT03267030) the safety and efficacy of eryaspase was evaluated in 55 patients (aged 1–45 years; median: 6.1 years) with non-high-risk ALL and hypersensitivity to asparaginase conjugated with polyethylene glycol (PEG-asparaginase). Eryaspase (150 u/kg) was scheduled to complete the intended course of asparaginase (1–7 doses) in two Nordic/Baltic treatment protocols. Forty-nine (96.1%) patients had asparaginase enzyme activity (AEA) ≥100 iu/l 14 ± 2 days after the first eryaspase infusion [median AEA 511 iu/l; interquartile range (IQR), 291–780], whereas six of nine (66.7%) patients had AEA ≥100 iu/l 14 ± 2 days after the fourth infusion (median AEA 932 iu/l; IQR, 496–163). The mean terminal half-life of eryaspase following the first infusion was 15.3 ± 15.5 days. Few asparaginase-related adverse events were reported; five patients (9.1%) developed clinical allergy associated with enzyme inactivation. Replacement therapy was successfully completed in 50 patients (90.9%). Eryaspase was well tolerated, and most patients had AEA levels above the therapeutic target after the first infusion. The half-life of eryaspase confirmed that a 2-week schedule is appropriate.

Published
2022

17. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

Author

Hammel, Pascal, primary, El-Hariry, Iman, additional, Macarulla, Teresa, additional, Garcia-Carbonero, Rocio, additional, Metges, Jean-Philippe, additional, Bouché, Olivier, additional, Portales, Fabienne, additional, Pazo Cid, Roberto A., additional, Mineur, Laurent, additional, Cubillo Gracian, Antonio Manuel, additional, Trouilloud, Isabelle, additional, Guimbaud, Rosine, additional, Tougeron, David, additional, Reina Zoilo, Juan Jose, additional, Feliu, Jaime, additional, Sauri, Tamara, additional, Fountzilas, Christos, additional, Kay, Richard, additional, Youssoufian, Hagop, additional, and Hidalgo, Manuel, additional

Published
2022
Full Text
View/download PDF

18. A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.

Author

Yin, Chao, primary, Marshall, John, additional, Macke, Laura, additional, Bouker, Kerrie, additional, He, Aiwu Ruth, additional, Weinberg, Benjamin Adam, additional, Weiner, Louis M., additional, Wang, Hongkun, additional, Badri, Nabeel, additional, Biswas-Baldwin, Nigel, additional, Hoke, Frank, additional, Youssoufian, Hagop, additional, El-Hariry, Iman, additional, and Noel, Marcus Smith, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results